Alzheimer's Disease
Conditions
Brief summary
Examination of the correlation between the cerebral bloodflow and the clinical change under treatment with Reminyl retard® and the prediction of clinical change by measuring the cerebral bloodflow in patients with mild to moderate Alzheimer's Disease
Interventions
DRUGReminyl retard
retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg
Sponsors
Federal Ministry of Health, Germany
University Hospital, Bonn
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Possible Alzheimer's Disease according to ICD-10 and NINCDS-ADRDA * Underwritten study consent * No treatment with acetylcholinesterase inhibitors * Mini-Mental-State Examination: 12-25 points * Age: 50-80 Years * Orale contraception for women of child-bearing age
Exclusion criteria
* Mental Disorders * Other Diseases of the CNS * Severe Illness * Contraindication for MRI-Scan * Contraindication for Galantamin (Reminyl retard®) * Participation at other clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cerebral perfusion | baseline and after 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Change of Alzheimer Disease Assessment Scale, cognitive part (ADAScog) | baseline, after 12 and 24 weeks |
| Alzheimer's Disease Functional Assessment and Change Scale (ADFACS) | baseline, after 12 and 24 weeks |
| Neuropsychiatric Inventory (NPI) | baseline, after 12 and 24 weeks |
| Mini-Mental-Status-Examination (MMSE) | baseline, after 12 and 24 weeks |
Countries
Germany
Outcome results
None listed